Taya Venture Capital
VC Fund
Taiwan, China
Taya Venture Capital is a VC fund in Taiwan focused on Biotechnology and Life Science. Taya Venture Capital Co., Ltd. is a subsidiary of Daya Wire & Cable Group and has focused on discovering and investing in industries with growth potential. The company owns several professional investment funds, including Taya Ventures , Taya Innovation , Taya Genesis, and other NT dollar funds, as well as Taya Venture, a US dollar fund .
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Taya Venture Capital invests in
Stages Taya Venture Capital invests in
Countries Taya Venture Capital invests in
Round sizes
Round size
- Seed
- $5M–$9.5M
- Series A
- $21M–$26M
Investment Focus
Industry
- Biotechnology 3 (60%)
- Life Science 2 (40%)
- Tourism 1 (20%)
- PropTech 1 (20%)
- Software 1 (20%)
Stage
- Series A 3 (60%)
- Seed 2 (40%)
Country
- United States 3 (60%)
- Taiwan 2 (40%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Syncell
|
Syncell is a life science technology company building products for next-generation spatial biology. Its pioneering Microscoop™ technology enables microscopy-guided nanoscale protein "scooping", making unbiased subcellular spatial proteomics discovery feasible for the first time. This technology can be applied to a broad range ofbiological problems to help understand molecular mechanisms, identify novel disease biomarkers, and reveal novel druggable targets. | $25.7M / Series A / Jun 30, 2025 | |
Apeximmune Therapeutics
|
Apeximmune Therapeutics is pioneering a new generation of therapeutic antibodies and biologics that harness the power of the immune system to deliver curative treatments for cancer and autoimmune disease. | $21.3M / Series A / Mar 31, 2025 | |
Immunwork
|
Immunwork develops innovative drugs that combine targeting and effector functions to enhance efficacy and safety. The company focuses on creating ultralong-acting analogues, such as TE-8214, an octreotide derivative, and TE-8035, a modified human insulin. Immunwork's drug pipeline addresses immune system diseases and leverages a proprietarytechnology platform. The company is involved in clinical trials to validate its therapeutic solutions. | $23.7M / Series A / Mar 08, 2022 | |
iStaging
|
iStaging is a leading provider of out-of-the-box augmented and virtual reality solutions. Headquartered in Taipei, Taiwan, we also have satellite offices in San Francisco, Shanghai and Paris. Our goal is to help people transcend space by crafting immersive visualization products that empower the world interact with distant places or objects. | $5M / Seed / Sep 06, 2016 | |
Protuoso Biosciences
|
Protuoso Biosciences is a biotechnology company developing next-generation multifunctional biologics designed to address complex disease biology. | $9.5M / Seed |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Taya Venture Capital invest in?
Taya Venture Capital invests primarily in Biotechnology, Life Science and Tourism startups, most often at Series A and Seed stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Taya Venture Capital's check size?
Taya Venture Capital typically joins rounds of $5M–$9.5M at Seed and $21M–$26M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Taya Venture Capital participates in.
When did Taya Venture Capital last invest?
The most recent investment recorded for Taya Venture Capital closed in Jun 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
